安诺优达基因科技 北京）有限公司

安诺优达基因科技成立于2012年，总部位于北京，为中国基因组行业知名企业、中国领先的NIPT服务商、亚洲一流的医学基因组中心，专注于新一代基因组学技术在人类医学健康和生命科学研究两大领域的产业化应用。 自成立以来，安诺优达被认定为国家高新技术企业、国家卫计委首批高通量测序临床应用试点单位，国家发改委首批“基因检测技术应用示范中心”，北京市发改委“精准医疗与基因工程北京市工程实验室”，北京生物医药产业跨越发展工程（G20工程）企业，北京科技研究开发机构，拥有博士后科研工作站，入选中国最具科技引领力企业30强、中国最具投资价值企业50强等。 立足于核心海内外人才团队，安诺优达拥有自主研发的领先基因组测序和生物信息学技术，推出了先进的桌面式高通量测序仪NextSeq 550AR（国械注准：20173400330）和生物大数据平台“安诺云”，已在测序设备和分子诊断试剂、医学检测与研究、科研服务、基因大数据和云平台服务等方面具备了优秀的产品体系和品牌效应，形成了覆盖业务上、中、下游的全产业链布局及强大的Bio-IT产业化服务能力，赢得了广大合作伙伴的高度认可。 Annoroad Gene Technology, founded in 2012 with headquarters in Beijing, is a well-known enterprise in China’s genomics industry, a leading NIPT service provider in China, and a best-in-class medical genomics center in Asia, which specializes in the application of next-generation genomics in human health and life science research. Since its founding, Annoroad has been recognized with a series of prestigious designations including national high-tech enterprise, one of the pilot organizations approved by the NHFPC (National Health and Family Planning Commission) to take part in the high-throughput sequencing clinical application, one of the first gene detection technology demonstration centers approved by the NDRC (National Development and Reform Commission), one of the Beijing Engineering Laboratory of Precision Medicine and Genetic Engineering approved by Beijing Municipal Development and Reform Commission, one of the enterprises included in the Beijing Biopharmaceutical Industry Leap-forward Development Program (G20 Program), Beijing Scientific and Technological R&D Institution. It has a post-doctoral scientific research station and is included in Top 30 Leading Technology Companies in China, and Top 50 Most Investment-Worthy Enterprises in China. Based on its core overseas and domestic talent teams, Annoroad has developed leading proprietary genome sequencing and bioinformatics technologies and established advanced high-throughput sequencing and high-performance computing platforms. Annoroad has launched NextSeq 550AR (CFDA No.:20173400330), a leading high-throughput benchtop sequencer, and SolarGenomics, a cloud-based genomic big data platform. Currently, Annoroad has put in place a comprehensive product system covering sequencing instrument and reagents, medical testing and research, scientific research service, Genomic big data service with a high reputation and built a strong presence along the upstream, midstream and downstream of the entire industry chain and powerful Bio-IT industrial service capabilities, which have been highly recognized by a wide range of partners.

According to the GICS (Global Industry Classification Standard) version of March 2023, 安诺优达基因科技 北京）有限公司’s industry classification falls within the following categories:

• Sector: -
• Industry group: -
• Industry: -
• Sub-Industry: -